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A serum-mediated mechanism for concomitant resistance shared by
immunogenic and non-immunogenic murine tumours
M Franco, OD Bustuoabad, PD di Gianni, A Goldman, CD Pasqualini and RA Ruggiero
Division Medicina Experimental, Instituto de Investigaciones Hematol6gicas, Academia Nacional de Medicina, Buenos Aires,
Argentina.
Summary Resistance of tumour-bearing mice to a second tumour challenge, that is concomitant resistance,
was evaluated in euthymic and nude mice using nine tumours with widely different degrees of immunogenicity.
Two temporally separate peaks of concomitant resistance were detected during tumour development. The first
one was exhibited only by small immunogenic tumours; it was tumour specific and mediated by classical
immunological T-cell-dependent mechanisms. The second peak was shared by both immunogenic and non-
immunogenic large tumours; it was non-specific, thymus independent and correlated with the activity of a
serum factor (neither antibody nor complement) that inhibited the in vitro proliferation of tumour cells. This
factor was eluted from a Sephadex G-15 column at fractions corresponding to a molecular weight of
approximately 1000 Da and it was recovered from a high-performance liquid chromatography column in one
peak presenting maximum absorption at 215 and 266 nm. The data presented in this paper suggest for the first
time, to our knowledge, that in spite of the differences between immunogenic and non-immunogenic tumours, a
common serum-mediated mechanism seems to underlie the concomitant resistance induced by both types of
tumours at late stages of tumour development.
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Concomitant resistance is the phenomenon according to
which a tumour-bearing host inhibits the growth of a
secondary implant of the same tumour at a distant site. It
can be induced by both immunogenic and non-immunogenic
tumours but the mechanisms involved have been reported to
be different. In effect, concomitant resistance induced by
strongly immunogenic tumours has been described as tumour
specific and mainly mediated by T-cell-dependent cytotoxic
mechanisms, not different from a classical immunological
rejection (Belehradek et al., 1972; Chandradasa, 1973; Tuttle
et al., 1983; North, 1984; Akporiaye et al., 1988). On the
other hand, concomitant resistance induced by weakly or
non-immunogenic tumours has been described as non-specific
and mediated by a cytostatic mechanism presumably
unrelated to any known conventional immunological
mechanism (Gorelik et al., 1981; Gorelik, 1983; Ruggiero et
al., 1985; Meiss et al., 1986; Bonfil et al., 1988). In a former
paper (Ruggiero et al., 1990) we demonstrated that the serum
from mice bearing non-immunogenic tumours exhibited a
growth-inhibitory activity (not attributable to cytotoxic
antibodies) on in vitro proliferation of tumour cells that
was proportional to the intensity of concomitant resistance.
As a continuation of our previous papers, the aim of this
study was to determine whether immunogenic tumours could
also induce a form of concomitant resistance similar to that
demonstrated for non-immunogenic tumours.
Materials and Methods
Animals
BALB/c mice of both sexes, 2-4 months old, were used
throughout. They were raised in our own colony and
maintained on Nutric pellets (Cordoba) and water ad
libitum. Nude BALB/c mice of both sexes, 2-4 months old
were obtained from the Comision Nacional de Energia
Atomica, Argentina, and kept under relatively aseptic
conditions. Parabiotic BALB/c mice were prepared by
joining pairs of BALB/c mice, 2-3 months old, in parabiotic
union involving the skin and peritoneal cavities; cross-
circulation is established around day 7 according to our
previous experience. Animals were age and sex matched
within each experiment.
Tumours
MC-B: fibrosarcoma induced in a 4-month-old BALB/c male,
2.5 months after the s.c. implantation of methylcholanthrene
crystals. It was used between s.c. passages 6 and 23.
MC-C: fibrosarcoma induced in a 5-month-old BALB/c male
3 months after the s.c. implantation of a methylcholanthrene
pellet. It was used between s.c. passages 5 and 20.
MC-D: fibrosarcoma induced in a 6-month-old BALB/c
male, 4 months after the implantation of a methylcholan-
threne pellet. It was used between s.c. passages 6 and 17.
M3: mammary adenocarcinoma that arose spontaneously in
a BALB/c female and maintained by s.c. syngeneic passages.
It was used between passages 61 and 71. More detailed
description of this tumour is given elsewhere (Klein et al.,
1980).
MNU-2.1: mammary adenocarcinoma induced by N-methyl-
N-nitrosourea (MNU) in a female BALB/c mouse as
described previously (Pazos et al., 1992). It was maintained
by s.c. passages in female syngeneic mice and used between
passages 2 and 10.
MNUMPA-1.1: mammary adenocarcinoma induced by
medroxyprogesterone acetate (MPA) and MNU in a
BALB/c female as described previously (Pazos et al., 1992);
it was maintained by s.c. passages in syngeneic female mice
and used between passages 2 and 12.
C7HI: highly metastatic mammary adenocarcinoma origi-
nated in a BALB/c female treated with 40 mg of MPA every
3 months for 1 year and maintained by syngeneic s.c.
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transplantation. It was used between passages 18 and 42.
More detailed description of this tumour is given elsewhere
(Bonfil et al., 1989; Kordon et al., 1991).
L15: lymphoid leukaemia of AKR (H-2k) origin, maintained
by s.c. syngeneic passages, of which passages 54-143 were
used. In this paper, L15 was studied as an allogeneic tumour
progressively growing in BALB/c (H-2d) mice, i.p. pretreated
with acellular extract (a.e.) of L15, 10-16 days before the s.c.
L15 implantation. Total protein content of a.e. was 700-
900 jug as estimated by the method of Lowry et al., 1951).
Detailed description of the preparation of the a.e. of L15 and
the rationale of this procedure in order to permit allogeneic
tumour growth are given elsewhere (Pasqualini et al., 1976;
Rao and Bonavida, 1976).
LB: T-lymphoid leukaemia that arose spontaneously in a 6-
month-old BALB/c male. It was maintained by s.c. serial
passages in syngeneic mice and was used between passages 69
and 170. More detailed description of this tumour is given
elsewhere (Ruggiero et al., 1985; Zahalka et al., 1993).
All tumours were kept biofrozen and were thawed and s.c.
passaged.
TD50 is defined as the number oftumour cells able to grow
s.c. in 50% of the mice.
Immunisation assays
Tumour implantation and excision Subcutaneous tumours
were surgically excised when their volume had reached 400-
600 mm3; 2 weeks later, tumour challenge was carried out in
the contralateral flank of the mice that had not relapsed.
Sublethaldoses Mice that had survived afirst tumourimplant
were reinoculated with various doses ofthe same tumour.
Irradiated cells Cell suspensions were irradiated with 90 Gy
in a plastic irradiation chamber; X-rays were generated in a
Philips 250/15 Radiotherapy apparatus at 220 kV, 14 mA,
and filtered with 1 mm Al. The dose rate was 3.15 Gy min-I
at a focus-target distance of 29 cm. Animals were pretreated
with two s.c. doses of 2-4 x 106 irradiated tumour cells, 7
and 14 days before tumour challenge.
Concomitant resistance assay
Mice received a s.c. tumour implant in the right flank followed,
at different intervals, by a second s.c. implant of the same
tumour in the left flank. Control mice were challenged only in
the leftflank. The titre ofconcomitant resistance wasdefined as
the ratio between TD50 of the second challenge in tumour-
bearing mice and TD50 in control mice, and expressed as a
function oftheprimary tumourvolume atthe dayofthe second
challenge.
Tumour volume was calculated according to the formula
of Attia and Weiss (1966); volume =0.4 (a b2), where a and b
are the larger and smaller diameters respectively.
Serum
Normal and tumour-bearing mice were bled through the
retro-orbital plexus. The blood was kept at room temperature
for 1 h for clotting. Serum obtained after centrifugation was
stored at -20°C until used. For in vitro assays, serum was
decomplemented at 56°C for 30 min.
Medium
The medium used was RPMI-1640 (Gibco, Grand Island,
NY, USA), with penicillin G sodium (10Ig ml-1),
streptomycin sulphate (25 ug ml-') and amphotericin B as
fungizone (25 jug ml-'). Medium was supplemented with 5%
fetal calf serum.
[3H]Thymidine uptake assay
Approximately 1.5 x 104 adherent tumour cells (MC-B, MC-C,
MC-D, MNU-2.1, MNUMPA-1.1, M3 and C7HI) were
seeded in 0.1 ml of medium in 96-well microtitre plates
(Coming, NY, USA). After 24 h, 0.1 ml of several 2-fold
dilutions of serum from normal or tumour-bearing mice were
added. Immediately afterwards, cultures were pulsed with
[3H]thymidine (Dupont, NEN Research Products, Boston,
MA, USA) at a final concentration of 1 1Ci ml-' and the
mixture was incubated at 37°C for 18-24 h in a 5% carbon
dioxide humidified atmosphere and harvested with an
automated cell harvester. Tumour cells growing in suspension
(L15 and LB) were seeded in the plates (1-2 x 105 cells per
well) simultaneously with the serum and the [3H]thymidine.
The radioactivity incorporated into the cells was counted in a
liquid scintillation Beta counter (Beckman). The assays were
usually carried out in triplicate or quadruplicate. The titre of
growth-inhibitory activity was defined as the reciprocal of the
serum dilution producing 50% inhibition of [3H]thymidine
uptake by tumour cells as compared with medium only, and
was expressed in GIU50 ml-1.
Complement-dependent cytotoxic assay
This test was carried out according to the method of Rao et
al. (1974). Briefly, 0.1 ml of 51Cr-labelled tumour cells were
incubated with 0.1 ml of serum for 1 h at 37°C in a 5%
carbon dioxide humidified atmosphere. Afterwards, cells were
centrifuged and then incubated with 0.1 ml of rabbit serum
as a complement source for another hour. Then, cells were
centrifuged and radioactivity in the supernatant was
measured in a Gamma counter (Beckman). Spontaneous
lysis occurred with medium only. Maximal lysis occurred
with Triton. The percentage ofspecific lysis was calculated as:
[(experimental c.p.m.-spontaneous c.p.m.) / (maximal
c.p.m.-spontaneous c.p.m.)] x 100. The titre of cytotoxic
antibodies against tumour cells labelled with 51Cr (Dupont)
was defined as the reciprocal of the serum dilution producing
50% of specific lysis and expressed as CU50 ml-'.
Cell-mediated cytotoxicity assay
A modification of the method of Brunner et al. (1968) was
used. Briefly, 0.1 ml of 51Cr-labelled tumour cells was
incubated with the same volume of different spleen cell
suspensions at an effector-target ratio of 100: 1, for 4 h at
37°C in a 5% carbon dioxide humidified atmosphere.
Afterwards, cells were centrifuged and radioactivity in the
supernatant was measured in a Gamma counter (Beckman).
Percentage of specific lysis was calculated as: [(experimental
c.p.m.-normal c.p.m.)/(maximal c.p.m.-normal c.p.m.)]
x 100. In order to measure natural killer (NK) activity,
51Cr-labelled YAC-1 cells were used as a target of cell-
mediated cytotoxicity.
Adoptive transference assay
Normal mice were inoculated i.v. with 108 spleen cells from
normal or tumour-bearing mice. After 2 h, passively
transferred mice were challenged with a s.c. tumour
implant. The survival index (SVI) was calculated as the
survival time in days divided by the ratio between the number
of mice that died of tumour and the total number of mice
inoculated. SVI is a measure of both the survival time and
the percentage of mortality.
Winn assay
The anti-tumour activity of spleen cells from normal or
tumour-bearing mice was investigated with the in vivo Winn
test (Winn, 1961) by mixing them with tumour target cells at
an effector-target ratio of 100:1. The cells were then
inoculated by the s.c. route and tumour growth evaluated.Concomitant resistance in murine tumours
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Serum fractionation
Dialysis Serum from normal and tumour-bearing mice was
subjected to dialysis (12 500 molecular weight cut-off).
Chromatography on Sephadex G-15 The dialysable fraction
of serum was concentrated by lyophilisation, resuspended in
0.5 ml of water and applied to a 66 x 0.7 cm chromato-
graphic column of Sephadex G-15; elution was performed
with water with a 0.44 ml min-' flow rate.
High-performance liquid chromatography (HPLC) Addi-
tional fractionation of serum was performed in a chromato-
graph model 140 from Applied Biosystems with a diodo
array detector, using an HPLC column C18, 22 x 0.21 cm;
elution was carried out with water in a gradient of
trifluoracetic acid and acetonitrile with a 0.15 ml min-
flow rate.
Each fraction obtained from Sephadex G-15 and HPLC
columns was assayed on in vitro proliferation of tumour cells
using the [3H]thymidine uptake assay. Elution solvents were
removed from HPLC fractions before the assay.
Statistical analysis
Student's t-test, X2-test and Spearman correlation test were
used. Differences were considered significant when P-value
was 0.05 or smaller.
Results
Immunogenicity ofnine murine tumours
Immunogenicity of nine murine tumours was studied in
BALB/c mice using three immunisation assays: tumour
implantation and excision, pretreatment with tumour
irradiated cells and pretreatment with tumour sublethal
doses. Similar results were obtained with the three
immunisation procedures and therefore their data were
pooled. Results are shown in Table I, where the increase in
TD50 after the immunisation procedures was taken as a
Table I Immunogenicity of nine murine tumours, expressed as the
increase in TD50 of tumours in immunised BALB/c mice, as
compared with control BALB/c mice
Ratio
TD50 (mean+s.e.) immunised
Tumours Control Immunised control
L15 leukaemia 224 000+ 55 000 >25000ooOa > 111.61
(n =52)b (n =47)
MC-D fibro- 54 500+6300 >2 690 oooa >49.36
sarcoma (n=45) (n= 14)
MC-C fibro- 50 900+ 8960 >2 240 OOOa >44.01
sarcoma (n =48) (n =27)
MNUMPA-1.1 42 800+±11 600 409 000±109000C 9.56
breast carcinoma (n =46) (n= 11)
MC-B fibro- 42 825 + 3550 232 000 169 000c 5.42
sarcoma (n =69) (n=36)
MNU-2.1 breast 45 600+7110 196 000i47 700C 4.30
carcinoma (n =42) (n =11)
M3 breast 18 500 +4900 43 300+ 12 000 2.34
carcinoma (n =32) (n =27)
C7HI breast 5500±800 6167+ 667 1.12
carcinoma (n =34) (n =22)
LB leukaemia 1170+ 110 1110+ 170 0.95
(n =64) (n =75)
ap<0.001 (t-test). bn =number ofmice. CP<0.05 (t-test).
measure of tumour immunogenicity; tumours were listed
according to their immunogenicity, from the most immuno-
genic (LI5) at the top to the less immunogenic (LB) at the
bottom of the table.
Concomitant resistance elicited by nine murine tumours
Euthymic and nude BALB/c mice were s.c. inoculated in the
right flank with 5 x 105 tumour cells from: L15 (n = 90 mice),
MC-D (n=93), MC-C (n=118), MNUMPA-1.1 (n=51),
MC-B (n = 115), MNU-2.1 (n =68), M3 (n =70), C7HI
(n =26) or LB (n =84). At different stages of tumour
growth, a second challenge with graded doses of cells of
the same tumour was carried out in the left flank. Control
mice [n =87 (for LI5); n=78 (MC-D); n= 144 (MC-C); n= 59
(MNUMPA-1.1; n=105 (MC-B); n=42 (MNU-2.1); n=80
(M3); n =25 (C7HI) and n = 182 (LB)] received the
'secondary' tumour challenge only. The increase in TD50 of
the secondary tumour in tumour-bearing mice as compared
with the control group was taken as a measure of
concomitant resistance. As can be seen in Figure 1, two
peaks of concomitant resistance could be detected during
tumour development: the first peak was observed when the
primary tumour was small at the moment of the second
challenge; it seemed to be thymus dependent as it was present
in euthymic but not in nude mice, and it was proportional to
tumour immunogenicity (P<0.0001, Spearman correlation),
that is, the more immunogenic the tumour, the higher the
first peak of concomitant resistance; reciprocally, when
tumour immunogenicity was weak (M3 tumour) or absent
(LB and C7HI tumours), the first peak did not appear. On
the other hand, the second peak was observed late during
tumour development, that is, when the primary tumour was
large; it seemed to be thymus independent as it was present in
both euthymic and nude mice, and it did not correlate with
tumour immunogenicity (P=NS, Spearman correlation); for
example, similar high values in the second peak of
concomitant resistance were obtained with L15 and LB in
spite of sharp differences in their tumour immunogenicity;
reciprocally, sharp differences in the second peak were seen
with LB as compared with C7HI in spite of their lacking any
detectable immunogenicity. It is noteworthy that the only
tumour that did not show concomitant resistance at any stage
of tumour development was the highly metastatic C7HI.
Figure 1 also reveals that between the first and the second
peak, concomitant resistance was weak or absent, with the
only exception being the L15 tumour, where it remained at a
high level throughout tumour development.
Histological studies have shown differences between the
first and the second peak of concomitant resistance. In effect,
histological examination of skin at the site of a 9 day MC-C
secondary implant revealed a profuse infiltration with host
cells (macrophages, polymorphonuclear granulocytes and
lymphocytes) if the second challenge was performed when
primary MC-C tumour was small. By contrast, no signs of a
conventional immunological rejection, with morphologically
well-preserved tumour cells, accompanied the growth
inhibition of the second tumour challenge if it was carried
out when the primary tumour was large. Similarly, lack of
cellular infiltration and a well-preserved state of secondary
tumour cells were observed in mice bearing the non-
immunogenic LB tumour at late stages of tumour develop-
ment. Preliminary evidence by flow cytometric analysis of the
secondary tumour has shown a lower percentage of tumour
cells in the S- G2- ad M-phases of the cell cycle (unpublished
results).
Non-specificity of concomitant resistance induced by large
tumours
BALB/c mice bearing a strongly immunogenic (L15 or MG-
C) or a weakly immunogenic (M3) tumour were challenged,
at different stages of tumour growth, with the immunologi-
cally unrelated (as determined by cross-immunisation assays)a)
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Figure 1 Concomitant resistance expressed as the ratio between TD50 of secondary tumour in tumour-bearing mice/TD5O in
control mice (ordinate). Abcissa indicates the primary tumour volume at the day of the second challenge. Each point represents the
mean+ s.e. of 2-5 experiments. For simplicity, ratios > 100 are shown as 100. Tumour-bearing euthymic BALB/c mice (0-0): first
peak of concomitant resistance was higher than control (- - -) for: MC-D (P<0.01), MC-C (P<0.05), MNUMPA-1.1 (P<0.05),
MC-B (P<0.01) and MNU-2.1 (P<0.05) (t-test); second peak was higher than control for all tumours except for C7HI (MC-D:
P<0.01, MC-C: P<0.05, MNUMPA-1.1: P<0.05, MC-B: P<0.05, MNU-2.1: P<0.05, M3: P<0.05 and LB: P<0.001 (t-test).
L15 showed significant concomitant resistance all along tumour development (P<0.001). Tumour-bearing nude BALB/c mice (0-
0): P<0.05 (t-test) only for the second peak for all tumours except for C7HI.
Table II Non-specificity of the second peak of conconitant
resistance. Mice bearing L15, MC-C or M3 tumours were
challenged with 5 x 104 LB or 1 x 105 MC-B tumour cells
Tumour takes of secondary tumour/total
Secondary Tumour
Primary tumoura LB MC-B
Control 65/79 10/10
L15 <500 mm3 9/10 ND
>2000 mm3 0/6b ND
MC-C <500 mm3 12/14 6/6
>2000 mm3 7/15c 1/5C
M3 <500 mm3 6/6 6/6
>2000 mm3 38d 2/6d
aprimary tumour
bp <0.00I (X2 test).
determined.
volume at the day of the secondary implant.
CP<0.01 (X2 test). dp<00.5 (X2 test). ND, not
LB or MC-B tumour. As shown in Table II, concomitant
resistance against a second implant with a different tumour
could only be observed when the primary tumour was large
at the time of the second implant. These observations suggest
that the first peak of concomitant resistance induced by
strongly immunogenic tumours (see Figure 1) was specific but
the second peak, shared by large tumours independently of
their immunogenicity, had some degree of non-specificity.
Humoral and cellular immunity in mice bearing immunogenic
tumours
Humoral immunity Serum from BALB/c mice bearing the
highly immunogenic L15 or MC-C tumour was studied at
different stages of tumour development, looking for cytotoxic
antibodies anti-L15 or anti-MC-C. The titre of cytotoxic
antibodies (CU5o ml-1) was determined using a 5'Cr release
assay. As shown in Figure 2, cytotoxic antibodies against L15
or MC-C cells were detected only when the tumour was
small. Concordant results were obtained with an immuno-
fluorescence assay (data not shown).
Cellular immunity As shown in Figure 2, spleen cells from
euthymic mice bearing small L15 or MC-C tumours exhibited
significant cytotoxicity against 5"Cr-labelled tumour cells.
Afterwards, when tumour size increased, this cytotoxic
activity soon disappeared in mice bearing MC-C tumour
whereas it slowly decayed but did not disappear, in mice
bearing L15 tumour. No in vitro anti-tumour cytotoxic
activity was ever detected when spleen cells from tumour-
bearing nude mice were used (data not shown).
Similar results were obtained when anti-tumour immunity
was tested using two in vivo assays: the adoptive transference
and the Winn test. In effect, as shown in Table III, significant
resistance to the development of s.c. 5 x 105 MC-C tumour
cells could be adoptively transferred by a single i.v. injection
of 108 spleen cells from mice bearing small MC-C tumours
but not from mice bearing large tumours. Similarly, when
50 x 106 spleen cells from mice bearing MC-C tumours were
assayed in a Winn test against MC-C tumour cells, only
spleen cells from mice bearing small tumours showed some
detectable anti-tumour activity.
In order to test natural killer (NK) activity, spleen cells
from MC-C-bearing mice were in vitro assayed against 51Cr-
labelled YAC-1 cells. In tumour-bearing euthymic mice, NK
activity was lower than normal at every stage of tumour
growth. In tumour-bearing nude mice, NK values higher than
normal were seen when MC-C was small; when MC-C was
larger NK activity gradually decreased to normal values (data
not shown).
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Inhibitory activity in serum of tumour-bearing hosts against
tumour cells in vitro
Serum collected from tumour-bearing BALB/c mice exhib-
ited, in a [3H]thymidine uptake assay, an inhibitory activity
on in vitro proliferation of the same tumour cells. Serum was
routinely decomplemented before use (when non-decomple-
mented serum was used, similar results were obtained). As
can be seen in Figure 3, this activity was proportional to
Tumour volume (mm3)
Figure 2 Cytotoxic activity in serum or spleen cells from
BALB/c mice bearing L15 (open symbols) or MC-C (filled
symbols) tumours, against 51Cr-labelled tumour cells. Comple-
ment-dependent cytotoxic antibodies: each point represents the
mean+s.e. of two experiments for L15 (0-0) or MC-C (0-0)
tumours. P<0.01 for small L15 tumour; P<0.05 for small MC-C
tumour (t-test). Cytotoxic activity of spleen cells: each point
represents the mean+s.e. of four determinations for L15 (El-El)
or MC-C (U--) tumours. (--- -: spleen cells from BALB/c mice
immunised against L15). P<0.01 for small MC-C and L15
tumours; P<0.05 for larger Ll5 tumours (t-test).
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tumour size (P<0.05, Spearman correlation); individual
values taken from one experiment chosen as example, are
shown in Table IV. This inhibitory activity correlated with
the intensity of the second peak of concomitant resistance
(P<0.02, Spearman correlation); that is, the higher the
second peak of concomitant resistance, the stronger the
inhibitory activity found in the serum of tumour-bearing
mice; for example, LB-bearing mice exhibited the highest
second peak of concomitant resistance (see Figure 1) and
Table III Adoptive transference of splenocytes and Winn test
against MC-C tumour
Survival indexa
Assay
Adoptive
Origin ofspleen cells transference Winn test
Normal mice 42.1±5.9 53.5+2.6
(n=6) (n =8)
Mice bearing MC-C tumour of 65.5 7.9b 110.8+16.lc
200-500 mm3 (n= 11) (n=7)
Mice bearing MC-C tumour of 78.6±6.5c 124.2 18.1C
700-900 mm3 (n= 10) (n=7)
Mice bearing MC-C tumour of 51.6+4.1 50.5± 1.5
2700-2900 mm3 (n=3) (n=2)
In the adoptive transference assay, normal BALBc/mice were i.p.
inoculated with 108 spleen cells from normal or MC-C bearing mice
and, 2h later, they received a s.c. challengewith 5 x 105 MC-C cells. In
the Winn test, 50 x 106 spleen cells and 5 x 105 MC-C cells were s.c.
innoculated together. aSurvival index: survival time in days/(t/n) ± s.e.
where t is the number of mice that died of tumour and n is the total
number ofmice inoculated. bp<0.05 (t-test). CP<0.001 (t-test).
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Figure 3 Growth-inhibitory activity of serum from tumour-bearing euthymic and nude BALB/c mice, measured by a [3H]thymidine
uptake assay and expressed as the ratio between GIU50 ml-l of serum from tumour-bearing euthymic (0-0) or nude (0-0) mice
and GIU50 ml-l of normal serum (---
- -). Each point represents the mean+ s.e. of 2-12 experiments. Number of tumour-bearing
mice used ranged from 20 to 124 per tumour. The titre of inhibitory activity reached the highest values when tumour became large:
L15: P<0.01, MC-D: P<0.05, MC-C: P<0.05, MNUMPA-l.1: P<0.05, MC-B: P<0.01, MNU: P<0.05, M3: P<0.01 and LB:
P<0.01 (t-test).
.MC-D
f--_____________
MC-C
_______
-----------------~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MNU-2.1
_ _ _ _ _ _ _ _ _ _ _ _ _
1
I
I 3
EConcomitant resistance in murine tumours
M Franco et a! 9
183
Table IV Effect of serum from BALB/c mice bearing MC-C tumour, on in vitro MC-C proliferation
3[H]thymidine z,ptake by MC-C cells (c.p.m. ±s.d.)a
Final serum dilution Group lb Group 2 Group 3d Normal serum
1:2 18 244±9126 17235± 2405 3734±497 47713± 3435
1:4 65804±9196 46892± 3539 20619±4877 68 134± 1315
1:8 83286± 3576 60916± 6327 36 193±4396 79042± 8056
1:16 91 148 ±7699 74732± 7744 54184± 3700 88787± 3504
GIU50 mlI1 31.5 43 126.7 20.5
Ratio 1.5 2.1 6.2 1
aEach value is the mean oftriplicate to sextuplicate measurements; c.p.m. incorporated by MC-C in medium only =95664± 3834. bSerum from
mice bearing an MC-C tumour of200-300 mm3. cSerum from mice bearing an MC-C tumour of 1500- 1800 mm3. dSerum from mice bearing an
MC-C tumour of2700-2900 mm3
tumours exhibited intermediate values in both the second
___-1_ _r LI __ __-- ._ _. __ _._---__ _ _ .1 _ *_1_1_ '--, ------,- ._- peak ot concomitant resistance and the innhibtory activity in
serum. The high titre of in vitro growth-inhibitory activity, as
evaluated by the [3H]thymidine uptake assay, found in sera
from mice bearing large tumours, (Figure 3) strongly
contrasts with the absence of cytotoxic antibodies as
evaluated by the 51Cr release assay in the same sera (Figure
2). Furthermore, sera from mice that had been immunised
against L15 (but not bearing the tumour) exhibiting a high
titre of cytotoxic antibodies (Figure 2), did not show any
inhibitory activity on in vitro tumour proliferation (data not
shown).
Similar results to those obtained in euthymic mice were
registered in nude mice (Figure 3), suggesting that this
inhibitory activity is thymus independent.
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Figure 4 Decay of serum growth-inhibitory activity and
abrogation of resistance to a 'second' tumour challenge in MC-
C tumour-excised mice. Twelve MC-C tumour-bearing mice
(1800-2000mm3) were divided into two groups: in six mice,
tumour was excised whereas in the remaining six mice, tumour
remained undisturbed. (a) Serum growth-inhibitory activity was
measured when tumour was present (day 0) or 5, 10 and 17 days
after tumour excision. Ordinates: ratio of GIU50 of serum from
tumour-excised mice to GIU5s of normal serum. Dashed line:
normal serum. Each bar represents the mean+s.e. of six sera.
Day 0: P<0.01 and day 5: P<0.05 as compared with normal
serum; days 10 and 17, P: NS. (b) Seven days after tumour
excision (indicated with the arrow), excised (n =6), tumour-
bearin,g (n =6) and control (n = 7) mice received an implant of
1 x 10 MC-C tumour cells in the opposite flank and tumour
growth of this implant was evaluated. f-f: tumour-excised. A-
A\: tumour-bearing. 0-0: control mice. Differences between
tumour-excised and tumour-bearing: P<0.01 at days 12, 15 and
20. Differences between tumour-excised and control were non
significant at every day tested.
correlatively their sera exhibited the strongest inhibitory
activity. Reciprocally, C7HI-bearing mice did not show the
second peak of concomitant resistance and correlatively their
sera did not exhibit any inhibitory activity. The remaining
Dependence on primary tumour Serum inhibitory activity
from mice bearing a large LB (>2000 mm3) tumour was
dependent on the presence of a growing tumour; in effect,
48 h after tumour excision, serum inhibitory activity
dropped from 223.2 +59.2 GIU50 ml (mean of three
experiments, ratio to normal serum: 7) to normal values
(32.1+5.6 GIU5o ml-'). Similar observations were carried
out in mice bearing a large MC-C tumour (>2000 mm3):
after tumour removal, titre of serum inhibitory activity
decayed progressively and, correlatively, resistance against a
'secondary' MC-C tumour challenge was abrogated. In
effect, while in tumour-bearing mice the second tumour
challenge was significantly inhibited, in tumour-excised and
normal mice it grew rapidly (Figure 4).
Transference of growth inhibitory activity Attempts to
transfer resistance against the MC-C tumour by serial i.v.
and i.p. inoculation of serum from mice bearing a large MC-
C tumour to normal mice, have been unsuccessful. However,
transference of resistance was carried out through cross-
circulation using parabiotic mice: four mice bearing an MC-C
tumour were joined in parabiosis with four normal mice.
Seven days later, when tumour volume was >2000 mm3,
normal partners of each pair received a challenge of 1 x 105
MC-C tumour cells and the growth of this challenge was
evaluated; four normal mice (ioined in parabiosis with a
normal partner) similarly challenged were used as control.
Fifteen days after challenge, tumour volume was
157.5+ 19.6 mm3 in normal partners of (tumour bear-
ing-normal) pairs, while it was 445.3+91.9 mm3 in control
mice (P<0.02; t-test). This mimicry ofconcomitant resistance
correlated with the appearance of serum growth- inhibitory
activity in the normal partner (83.4+ 13.6 GIU50 ml-'; ratio
to normal serum: 2.2; P<0.05), transferred from the MC-C-
bearing partner (122.1+37.9 GIU_o ml-'; ratio to normal:
3.2). Titre in normal mice was 38.5+ 1.4 GIU50 mI-1.
Non-specificity Serum from mice bearing an MC-C tumour
>2000 mm3 inhibited the in vitro proliferation not only of
the proper MC-C but also of the unrelated LB tumour cells
using the [3H]thymidine uptake assay. Titre of MC-C serum
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against MC-C (mean+s.e. of three experiments) was
202.9+12.1 GIU50 ml-1 (ratio to normal serum: 4.4;
P<0.01) and against LB (mean+s.e. of three experiments)
was 161.7+33.7 GIU50 ml-' (ratio to normal serum: 3.1;
P<0.05). The non-specific in vitro inhibition of LB tumour
cell proliferation by serum from mice bearing a large MC-C
tumour paralleled the non-specific in vivo inhibition of a
second implant of LB in mice bearing a large MC-C tumour
(see Table II).
Physicalproperties and serumfractionation Serum from mice
bearing an MC-C tumour >2000 mm3 was subjected to
dialysis (12 500 molecular weight cut-off). The inhibitory
activity, as evaluated by the [3H]thymidine uptake assay, was
only detected in the dialysable fraction, indicating a
molecular weight below 12 500. Additionally, this serum
activity proved to be resistant to heating at 56°C for 30 min
and at 100°C for 5 min, and it remained stable when samples
were stored for 2 days at 4°C. Similar properties were
exhibited by the growth-inhibitory activity found in serum
from mice bearing the non-immunogenic LB tumour
(Ruggiero et al., 1990). Partial purification of this inhibitory
activity was initiated: the active dialysable fraction of serum
was concentrated by lyophilisation and applied to a column
of Sephadex G-15, and one peak of inhibitory activity was
eluted at fractions corresponding to a molecular weight of
approximately 1000. This peak was lyophilised and further
purified with an HPLC column; 23 peaks were obtained but
growth-inhibitory activity (143.5+13.5 GIU50 ml-', ratio to
normal values: 7.2; n= 3 experiments; P<0.001) was
recovered in only one (peak number 8), which presented
maximum absorption at 215 and 266 nm (Figure 5).
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Figure 5 HPLC elution profile of the growth-inhibitory activity
found in the serum from LB tumour-bearing mice. The growth-
inhibitory activity of each fraction was assayed on LB tumour
cells using the [3H]thymidine uptake assay. Arrow indicates the
only fraction (number 8) with inhibitory activity. Absorbance was
registered at 215 (a) [(-
- - -), acetonitrile] and 266 (b) nm. Inset:
Absorption pattern of fraction number 8.
Discussion
Concomitant resistance has been described in mice bearing
both immunogenic and non-immunogenic tumours, but to
date, the mechanisms involved had been reported as being
very different. In this paper, using nine murine tumours with
different degrees of immunogenicity, we have tested whether,
besides those differences, a common mechanism could
underlie the concomitant resistance induced by all tumours,
independently of their immunogenicity.
Our results suggest that, during the primary tumour
development, two temporally separate peaks of concomitant
resistance can be detected. The first peak was observed when
the primary tumour was small; it was tumour specific and
thymus dependent as it was present in euthymic but not in
nude mice; its intensity was proportional to tumour
immunogenicity and a typical immunological rejection was
observed histologically at the site of the second tumour
implant undergoing concomitant resistance. Furthermore, the
kinetics of appearance and disappearance of the first peak of
concomitant resistance paralleled the kinetics of appearance
and disappearance of cytotoxic antibodies and cell-mediated
cytotoxicity against the tumour; NK cells did not seem to
play a main role. On the other hand, the second peak of
concomitant resistance was induced by both immunogenic
and non-immunogenic large tumours; it was non specific and
thymus independent as it was exhibited in both euthymic and
nude mice and it did not correlate with tumour immuno-
genicity; neither cytotoxic antibodies nor cellular immune
responses were involved. No host cell infiltration but
morphologically well-preserved tumour cells were histologi-
cally detected at the site of the second tumour implant
undergoing concomitant resistance, suggesting a cytostatic
mechanism. The intensity of the second peak of concomitant
resistance correlated with the activity of serum factors
(different from antibodies or complement) that inhibited the
in vitro proliferation of tumour cells; that is, the higher the
second peak, the stronger the inhibitory activity. Recipro-
cally, when this serum inhibitory activity was absent (the only
case was the highly metastatic C7HI tumour) the second peak
did not appear.
The relationship between the second peak of concomitant
resistance and serum inhibitory factors is additionally
supported by the following evidence: (a) the in vivo non-
specific resistance to a second tumour challenge paralleled the
in vitro non-specific antiproliferative activity by serum from
mice bearing large tumours; (b) removal of a large tumour-
immunogenic or non-immunogenic-was accompanied by a
decay in the inhibitory activity in serum simultaneously with
the disappearance of resistance to a second tumour challenge;
(c) transference of both serum growth-inhibitory activity and
resistance to a tumour challenge from immunogenic or non-
immunogenic tumour-bearing to normal mice was achieved
by cross-circulation using parabiotic mice.
Serum inhibitory factors from mice bearing both
immunogenic and non-immunogenic tumours proved to be
heat resistant and dialysable; further purification showed that
this inhibitory activity was eluted from a Sephadex G-15
column at fractions corresponding to a molecular weight of
approximately 1000 and it was recovered from an HPLC
column in only one peak presenting maximum absorption at
215 and 266 nm. Although final purification and character-
isation of this factor(s) is the subject of a forthcoming paper,
data presented here suggest that previously characterised
growth inhibitors such as interferons, tumour necrosis
factors, the transforming growth factor beta family
(Trincheri and Perussia, 1985; Beutler and Cerami, 1986;
Keski-Oja et al., 1988) and the novel angiostatin (O'Reilly et
al., 1994) would not be involved because of their larger
molecular weight and other physical properties (e.g. tumour
necrosis factors, the transforming growth factor beta family
and angiostatin do not resist boiling). The source of this
inhibitory activity remains speculative; up to now it has been
only occasionally recovered in conditioned medium of MC-C
DConcomtnt resiaace - muruie tumous
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and LB cultures: on the other hand, thymectomy or
splenectomy did not alter the titre of serum growth-
inhibitory activity (unpublished results). The fact that the
serum inhibitory activity disappears after tumour excision
could suggest that the tumour cells are responsible for its
elaboration: however, an indirect effect of the tumour on the
microenvironment can not be discarded.
Previous studies using non-immunogenic tumours have
described the existence of concomitant resistance at late
stages of tumour growth (here referred to as second peak of
concomitant resistance) and a serum-mediated mechanism
was suggested (Ruggiero et al.. 1990: Prehn. 1993). On the
contrary. most of the authors studying concomitant
resistance induced by strongly immunogenic tumours have
described the existence of the first peak but not that of the
second peak of concomitant resistance (Belehradek et al..
1972: Chandradasa, 1973; Vaage, 1973: Howell et al.. 1975:
Berendt et al., 1978: Leveson et al., 1979: Finlay-Jones et al..
1980: Tuttle et al.. 1983). There are three possible
explanations for this. First, many of these studies were
restricted to relatively early stages of tumour development
(Belehradek et al.. 1972; Chandradasa, 1973; Vaage. 1973:
Howell et al., 1975: Berendt et al.. 1978; Leveson et al.. 1979:
Finlay-Jones et al.. 1980). Second, the evaluation of
concomitant resistance was often not completely adequate:
in effect, most of those studies were carried out using only
one dose of tumour cells as the second challenge (Vaage.
1973: Howell et al.. 1975: Berendt et al.. 1978; Leveson et al..
1979: Finlay-Jones. 1980). Third. in some experiments.
concomitant resistance could not be strictly tested as the
primary tumour was excised soon after the second challenge
(Vaage. 1973. 1977). Our results, describing two temporally
separate peaks of concomitant resistance. may explain
apparently contradictory results reported by different
authors: for example. both Berendt et al. (1978) and Gorelik
(1983) have worked with the same tumour, the strongly
immunogenic Meth A. using similar tumour doses for the
first and the second challenges: however, whereas Berendt et
al. stated that resistance to a second Meth A tumour
challenge was observed transiently in mice bearing a very
small Meth A tumour. Gorelik stated that resistance to a
second Meth A tumour challenge did not appear when the
primary tumour was small while its intensity was progres-
sively higher as the primary tumour became larger. In our
opinion, the reason for these seemingly contradictory
conclusions resides in the different stages of primary tumour
growth at which each of these authors has looked for
concomitant resistance. Other examples of apparently contra-
dictory but in fact, in our opinion, complementary results.
are found in papers studying concomitant resistance
associated with melanoma B16 (Leveson, 1979: Gorelik et
al.. 1981), murine lung Lewis carcinoma 3LL (De Wys. 1972:
Gorelik, 1981), rat carcinoma of Flexner-Jobling (Woglom.
1929). methylcholanthrene-induced fibrosarcomas (Deckers et
al.. 1973; Kearney and Nelson, 1973; Nomi et al., 1986).
In conclusion, the data presented in this paper suggest for
the first time, to our knowledge, that besides the classical
immunological mechanism of concomitant resistance induced
by small immunogenic tumours, a common mechanism.
mediated by serum factors of low molecular weight. seems
to underlie the concomitant resistance induced by both
immunogenic and non-immunogenic tumours at late stages
of primary tumour development.
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